-
Swiss Von Allmen pips Odermatt to Val Gardena downhill
-
Vonn claims third podium of the season at Val d'Isere
-
India drops Shubman Gill from T20 World Cup squad
-
Tens of thousands attend funeral of killed Bangladesh student leader
-
England 'flat' as Crawley admits Australia a better side
-
Australia four wickets from Ashes glory as England cling on
-
Beetles block mining of Europe's biggest rare earths deposit
-
French culture boss accused of mass drinks spiking to humiliate women
-
NBA champions Thunder suffer rare loss to Timberwolves
-
Burning effigy, bamboo crafts at once-a-decade Hong Kong festival
-
Joshua knocks out Paul to win Netflix boxing bout
-
Dogged Hodge ton sees West Indies save follow-on against New Zealand
-
England dig in as they chase a record 435 to keep Ashes alive
-
Wembanyama 26-point bench cameo takes Spurs to Hawks win
-
Hodge edges towards century as West Indies 310-4, trail by 265
-
US Afghans in limbo after Washington soldier attack
-
England lose Duckett in chase of record 435 to keep Ashes alive
-
Australia all out for 349, set England 435 to win 3rd Ashes Test
-
US strikes over 70 IS targets in Syria after attack on troops
-
Australian lifeguards fall silent for Bondi Beach victims
-
Trump's name added to Kennedy Center facade, a day after change
-
West Indies 206-2, trail by 369, after Duffy's double strike
-
US strikes Islamic State group in Syria after deadly attack on troops
-
Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients
-
Epstein files opened: famous faces, many blacked-out pages
-
Ravens face 'special' Patriots clash as playoffs come into focus
-
Newly released Epstein files: what we know
-
Musk wins US court appeal of $56 bn Tesla pay package
-
US judge voids murder conviction in Jam Master Jay killing
-
Trump doesn't rule out war with Venezuela
-
Haller, Aouar out of AFCON, Zambia coach drama
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
Bologna win shoot-out with Inter to reach Italian Super Cup final
-
Brandt and Beier send Dortmund second in Bundesliga
-
Trump administration begins release of Epstein files
-
UN Security Council votes to extend DR Congo mission by one year
-
Family of Angels pitcher, club settle case over 2019 death
-
US university killer's mystery motive sought after suicide
-
Rubio says won't force deal on Ukraine as Europeans join Miami talks
-
Burkinabe teen behind viral French 'coup' video has no regrets
-
Brazil court rejects new Bolsonaro appeal against coup conviction
-
Three-time Grand Slam winner Wawrinka to retire in 2026
-
Man Utd can fight for Premier League title in next few years: Amorim
-
Pandya blitz powers India to T20 series win over South Africa
-
Misinformation complicated Brown University shooting probe: police
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
US halts green card lottery after MIT professor, Brown University killings
-
Stocks advance as markets cheer weak inflation
-
Emery says rising expectations driving red-hot Villa
-
Three killed in Taipei metro attacks, suspect dead
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
M.King--AT